Saarland University

University of Saarland chooses Sectra Education Portal to bridge the gap to clinical reality for radiographer students

Retrieved on: 
Monday, February 19, 2024

LINKÖPING, Sweden, Feb. 19, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide the University of Saarland with its platform for medical education — Sectra Education Portal.

Key Points: 
  • LINKÖPING, Sweden, Feb. 19, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide the University of Saarland with its platform for medical education — Sectra Education Portal.
  • By adding Sectra's solution for medical education to their existing Sectra enterprise imaging solution, they are bridging the gap between education and the clinical reality.
  • Saarland University (UdS) is a public research university organized into six faculties covering all major scientific fields.
  • One of these being the Faculty of Medicine, which is located together with Saarland University Hospital (UKS) in Homburg/Saar in Germany.

EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle

Retrieved on: 
Friday, March 31, 2023

Munich, March 30, 2023 – Claudia Schmitt will become the new CFO of Siltronic AG effective July 1, 2023.

Key Points: 
  • Munich, March 30, 2023 – Claudia Schmitt will become the new CFO of Siltronic AG effective July 1, 2023.
  • She succeeds Rainer Irle (53), who has been CFO of Siltronic AG since 2013 and will leave the company at his own request.
  • "We are very pleased to introduce Claudia Schmitt as an experienced successor to Rainer Irle from Siltronic's own ranks," said Dr. Tobias Ohler, Chairman of the Supervisory Board of Siltronic AG.
  • "With Claudia Schmitt, an excellent choice was made as successor to my Executive Board colleague Rainer Irle.

ThinkCyte Broadens Advisory Board with the Appointments of Dr. Diether Recktenwald, Ph.D. and Dr. Bo Saxberg, M.D. Ph.D.

Retrieved on: 
Monday, January 23, 2023

The appointments complement the strengths of ThinkCyte's existing advisory team and bring deep experiential insights into emerging flow cytometry markets, strategic product development, and clinical applications to ThinkCyte's SAB.

Key Points: 
  • The appointments complement the strengths of ThinkCyte's existing advisory team and bring deep experiential insights into emerging flow cytometry markets, strategic product development, and clinical applications to ThinkCyte's SAB.
  • "I was honored to join ThinkCyte's Advisory Board to contribute to their excellent team's approach and vision," said Dr. Recktenwald.
  • I look forward to working with the extremely accomplished team as a member of the Advisory Board to help bring this vision to reality."
  • Recktenwald and Saxberg join our SAB alongside a team of renowned interdisciplinary experts in technology and science," said Janette Phi, Chief Business Officer at ThinkCyte.

MeMed to Participate in Upcoming Conferences

Retrieved on: 
Friday, April 29, 2022

Location: Megaron Athens International Conference Centre, Athens, Greece, and online

Key Points: 
  • Location: Megaron Athens International Conference Centre, Athens, Greece, and online
    E-Poster Discussion Presentation: A host-protein test based on TRAIL, IP-10 and CRP differentiates between adenoviral and bacterial-adenoviral co-infections in children with positive PCR-adenovirus detection
    Dr.CihanPapan, Senior physician at Saarland University Hospital, Germany

Preclinical Study Provides Guidance for Optimizing Safety and Efficacy of Endovascular Hepatic Denervation Devices to Treat Diabetes

Retrieved on: 
Wednesday, January 26, 2022

In order to aid in development of a novel hepatic denervation therapy for diabetes mellitus in particular, we conducted a digital morphometric analysis of the tissue surrounding human common hepatic arteries, providing the basis for the development of dedicated technologies and techniques to organ specific denervation.

Key Points: 
  • In order to aid in development of a novel hepatic denervation therapy for diabetes mellitus in particular, we conducted a digital morphometric analysis of the tissue surrounding human common hepatic arteries, providing the basis for the development of dedicated technologies and techniques to organ specific denervation.
  • To provide guidance for both efficacy and safety, we utilized an approach involving a combination of classical gross anatomy and histopathology with immunostaining and image analysis, said John Keating, DVM, DACVP , co-author and Director of Pathology at CBSET.
  • Our data indicate that the common hepatic artery is not only a rich, but also an accessible target for sympathetic modulation by denervation regardless of sex and diabetic status, with efficacy and safety most optimally balanced within the proximal hepatic artery.
  • This study leveraged our deep experience in preclinical evaluation of denervation therapies and could not have been performed in a timely manner without the digital morphometry techniques we developed in-house.

ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the Treatment of Hypertension in Europe

Retrieved on: 
Wednesday, October 6, 2021

ReCor Medical, Inc. (ReCor), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the companys Paradise Ultrasound Renal Denervation System (the Paradise System) is now available for the treatment of uncontrolled hypertension in Germany.

Key Points: 
  • ReCor Medical, Inc. (ReCor), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the companys Paradise Ultrasound Renal Denervation System (the Paradise System) is now available for the treatment of uncontrolled hypertension in Germany.
  • We are pleased to be one of the first hospitals in Europe to offer renal denervation with ultrasound.
  • Paradise ultrasound renal denervation is a device-based, minimally invasive procedure for the treatment of high blood pressure.
  • With its Paradise System ReCor has pioneered the minimally invasive use of ultrasound in renal denervation to treat patients with hypertension.